NCT06256523View on ClinicalTrials.gov

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

GZR18

0.5mg-13mg

OTHER

Placebo

administered the same volume as GZR18

Trial Locations (1)

Unknown

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY